Personal Genome Diagnostics Inc. (PGDx), a leader in cancer
genomics, announced today that it has entered into a collaboration with QIAGEN to provide comprehensive
genomic profiling tests and clinical decision support to molecular labs.
Under the non-exclusive agreement, PGDx will be responsible for the distribution of the PGDx elio™
oncology products and kitted solutions. Laboratories that purchase the PGDx elio products will have an
option to receive from QIAGEN standardized reporting, driven by professional guidelines for streamlined
case review and sign-out. In addition, laboratories will receive access to QIAGEN’s QCI Interpret One for
rapid, evidence-based reporting for next-generation sequencing (NGS) oncology tests at scale. Advancing
cancer diagnostics and making precision medicine more accessible to healthcare systems, laboratories,
and patients worldwide is a key focus of both parties